With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for Boomer and Gen X retirees. Without some degree of growth, portfolios built solely for income could lose the race as inflation erodes purchasing power. The Dividend Aristocrats didn't earn their title in a bull market. They earned it by surviving everything the modern economy has thrown at them: the dot-com collapse, the 2008 financial crisis, a once-in-a-century pandemic, and the most aggressive rate-hiking cycle in decades. Through every one of those storms, they didn't just survive; they kept writing bigger checks to their shareholders. That's not luck. That's the result of durable business models, conservative balance sheets, and management teams disciplined enough to protect the dividend when it would have been easier not to.

The Dividend Aristocrats offer dependable income because they have consistently raised their dividends.

With inflation not contained and energy prices spiking, Boomers and retirees need some portfolio growth to complement dividend income.

The safest Dividend Aristocrats offer solid total return potential, with a degree of safety unmatched.

A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here.

Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason. The 69 companies that made the cut for the 2026 S&P 500 Dividend Aristocrats list have increased their dividends (not just maintained them) for 25 consecutive years. But the requirements go even further, with the following attributes also mandatory for membership on the dividend aristocrats list:

Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement

Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.

Companies must be worth at least $3 billion for each quarterly rebalancing.

Average daily volume of at least $5 million transactions for every trailing three-month period at every quarterly rebalancing date.

Be a member of the S&P 500

Retirees often hunt for the biggest yield on the screen, and that instinct can lead straight into a dividend trap. A stock yielding 9% is usually a sign that something is wrong. The Aristocrat approach is more patient. A dividend in the 2–3% range that grows every year, paired with modest price appreciation, can deliver a total return of 5–8% annually, and that's enough to stay ahead of inflation and generate income without drawing down principal. For a retiree, that's worth far more than a flashy yield that gets cut the moment business softens.

We screened the 2026 Dividend Aristocrats for the safest companies with growth potential. Five hit our screens, all are Buy-rated at top Wall Street firms, and all make sense for Boomer and Gen X retirees looking to generate consistent dividends and total return to keep pace with inflation. Total return is a comprehensive measure of investment performance, which encompasses interest, capital gains, dividends, and distributions realized over time.

Procter & Gamble was founded more than 185 years ago as a soap-and-candle company. It has paid dividends to shareholders since 1891, raised them for 70 straight years, and currently pays a 2.89% dividend.  Procter & Gamble (NYSE: PG) focuses on providing branded consumer packaged goods worldwide. This is one of the most widely held Dividend Kings, with a portfolio of essential consumer brands that generate steady cash flow through all economic cycles. Procter & Gamble remains a favorite among retirees because its products are used in millions of households every single day. Even during economic downturns, consumers continue buying P&G products, which helps support reliable dividend payments.

The Company’s segments include:

Beauty

Grooming

Health Care

Fabric & Home Care

Baby

Feminine & Family Care

The Company’s products are sold in approximately 180 countries and territories primarily through mass merchandisers, e-commerce, including social commerce channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, including airport duty-free stores, high-frequency stores, pharmacies, electronics stores, and professional channels.

It also sells directly to individual consumers. It has operations in approximately 70 countries.

Procter & Gamble offers products under these brands and others, such as:

Head & Shoulders

Herbal Essences

Pantene

Rejoice

Olay,

Old Spice

Safeguard

Secret

SK-II

Braun

Gillette

Venus

Crest

Oral-B

Ariel

Downy

Gain

Tide

Always

Always Discreet

Tampax

Bounty

Wells Fargo has an Overweight rating with a $177 target price objective.

The Coca-Cola Company is an American multinational corporation founded in 1892. This company has been a long-time top holding of Warren Buffett and Berkshire Hathaway, and it pays a reliable 2.71% dividend. He owns a massive 400 million shares, which is 9.3% of the float and 9.9% of the portfolio. Organic revenue rose 5% in 2025, and the company anticipates 4–5% growth in 2026, with analysts projecting adjusted EPS growth of 7–8%. With a 63-year streak of increases and a business model built on recurring consumption, Coca-Cola combines defensive characteristics with exposure to emerging market growth.

The Coca-Cola Company (NYSE: KO) is the world's largest beverage company, offering consumers more than 500 sparkling and still brands, and pays a dependable 2.74% dividend.

Led by Coca-Cola, one of the world's most valuable and recognizable brands, the Company's portfolio features 20 billion-dollar brands, including:

Diet Coke

Coca-Cola Light

Coca-Cola Zero Sugar

Caffeine-free Diet Coke

Cherry Coke

Fanta Orange

Fanta Zero Orange

Fanta Zero Sugar

Fanta Apple

Sprite

Sprite Zero Sugar

Simply Orange

Simply Apple

Simply Grapefruit

Fresca

Schweppes

Dasani

Fuze Tea

Glacéau Smartwater

Glacéau Vitaminwater

Gold Peak

Ice Dew

Powerade

Topo Chico

Minute Maid

Globally, they are the No. 1 provider of sparkling beverages, ready-to-drink coffees, juices, and juice drinks.

Through the world's most extensive beverage distribution system, consumers in more than 200 countries enjoy the company’s beverages at a rate of over 1.9 billion servings per day. It’s also important to remember that the company owns 16% of Monster Beverage (NASDAQ: MNST), which continues to deliver strong financial results.

Jefferies has a Buy rating and set a target price of $90.

Johnson & Johnson is a multinational American corporation specializing in pharmaceuticals, biotechnology, and medical devices. With shares trading at 14.5 times forward earnings and paying a 2.14% dividend, this diversified healthcare giant is a strong buy at current prices.  Johnson & Johnson (NYSE: JNJ) is among the most conservative of the major pharmaceutical companies, with a diverse product portfolio and a familiar, solid brand. The company researches, develops, manufactures, and sells a range of healthcare products. Its primary focus is on products related to human health and well-being. Johnson & Johnson carries a payout ratio of just 47%, meaning the company is paying out less than half its earnings as dividends, which is a very healthy cushion.

It operates through two segments:

Innovative Medicine

MedTech

The Innovative Medicine segment is focused on various therapeutic areas, including:

Immunology

Infectious diseases

Neuroscience

Oncology

Pulmonary hypertension

Cardiovascular and metabolic diseases.

Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

The MedTech segment encompasses a diverse portfolio of products used in orthopedics, surgery, interventional solutions, cardiovascular intervention, and vision care. It also offers a commercially available intravascular lithotripsy (IVL) platform for the treatment of coronary artery disease (CAD) and peripheral artery disease (PAD).

HSBC has a Buy rating with a $280 target price.

Realty Income is a real estate investment trust that has paid monthly dividends consistently for over 55 years. It owns over 15,000 properties leased primarily to defensive retailers. This is an ideal stock for growth and income investors seeking a safer contrarian idea for the rest of 2026, with a 5.34% dividend yield. Realty Income Corporation (NYSE: O) is an S&P 500 company that acquires and manages freestanding commercial properties that generate rental revenue under long-term net lease agreements with its commercial clients. Realty Income stands out because it pays dividends monthly rather than quarterly, which retirees often find helpful for budgeting. Its long-term net-lease structure provides predictable rental income, and the company has increased its dividend more than 120 times since going public.

It is engaged in a single business activity: leasing property to clients, generally on a net basis. This business activity spans various geographic boundaries and encompasses a range of property types and clients across multiple industries.

The Company owns or holds interests in approximately 15,621 properties in:

All 50 United States

The United Kingdom

France

Germany

Ireland

Italy

Portugal

Spain

With clients operating in 89 industries, its property types include retail, industrial, gaming, and other categories such as agriculture and office.

Its primary industry concentrations include:

Grocery stores

Convenience stores

Dollar stores

Drug stores

Home improvement stores

Restaurants

Quick service

UBS has a Buy rating with a $72 target price.

AbbVie is ranked sixth among the largest biomedical companies by revenue. This stock is one of the top pharmaceutical stock picks on Wall Street and is an excellent choice for long-term, forever ownership with a reliable 3.12% dividend.  AbbVie Inc. (NYSE: ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. Few dividend stories in the market match what AbbVie has delivered since spinning off from Abbott Laboratories in 2013. The dividend has grown from $1.60 per share to a projected $6.92 in 2026, more than a fourfold increase in roughly a decade, compounding at better than 15% annually. That kind of dividend growth doesn't just keep pace with inflation; it runs laps around it.

The company offers:

Humira, an injection for autoimmune and intestinal Behçet's diseases and pyoderma gangrenosum

Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease

Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma

Elahere to treat cancer

Venclexta/Venclyxto to treat blood cancers.

It also provides:

Facial injectables, plastics and regenerative medicine, body contouring, and skin care products

Duopa and Duodopa to treat advanced Parkinson's disease

Ubrelvy for the acute treatment of migraine in adults

Qulipta for episodic and chronic migraine

Botox is therapeutic for depressive disorder

In addition, the company offers Ozurdex for eye diseases, as well as Lumigan/Ganfort and Alphagan/Combigan for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also offers Restasis to increase tear production, along with other eye care products.

Further, it provides:

Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection

Creon, a pancreatic enzyme therapy

Lupron to treat advanced prostate cancer, endometriosis, and central precocious puberty, and patients with anemia caused by uterine fibroids

Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation

Synthroid for hypothyroidism

Piper Sandler has an Overweight rating on the shares with a big $299 target price.

Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.

And no, it’s got nothing to do with increasing your income, savings, clipping coupons, or even cutting back on your lifestyle. It’s much more straightforward (and powerful) than any of that. Frankly, it’s shocking more people don’t adopt the habit given how easy it is.